Immune design corp

Immune Design Corporation develops therapeutic vaccines. The Company creates synthetic compounds to boost the effectiveness of vaccines and technology designed to trigger a specific immune defense. IMDZ) stock, price quote and chart, trading and investing tools. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms.

Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.

IMDZ ) (Delayed Data from NSDQ). IMMUNE DESIGN CORP annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Merck to Buy Immunotherapy Developer Immune.

Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. Delaware corporation (the “ Company ”), hereby grants an option to purchase shares of its common stock, par value $0. Option”), to the optionee named below, subject to the vesting and other conditions set forth below.

Carlos has jobs listed on their profile.

See the complete profile on LinkedIn and discover Carlos. The EMA designation is normally assigned to products targeting the treatment of rare medical. Securities and Exchange Commission (SEC).

Continue reading the main story. Delaware Corporation (the “ Corporation ”), hereby certifies as follows. Of this total $386was received as a salary , $150was received as a bonus, $271was received in stock options, $122was awarded as stock and $16came from other types of compensation. NASDAQ:IMDZ) Files An 8-K Completion of Acquisition or Disposition of AssetsItem 2. Biotechnology and pharmaceutical news, data and analysis about biotech companies, biotech investors, biotech research and development, clinical trials, and the FDA. Free forex prices, toplists, indices and lots more.

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. The entity status is Active. T cells to fight cancer via distinct mechanisms. The of the Federal Trade Commission , protecting America’s consumers for over 1years. K Annual Report: Financial - Expense Highlight Net cash used in operating activities was $35.

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Immunomedics Inc. The Company is focused on the development of immune -based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions.

South San Francisco, CA. OMNIBUS INCENTIVE PLAN. NON-QUALIFIED OPTION AGREEMENT. Find companies that have a similar focus to IMDZ. Overall Job Satisfaction: 4. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price.

Common Stock We are offering shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. We anticipate that the initial public offering price of our shares of common stock will be between $ and $ per share.

SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. Every immune system has a story to tell. The key is knowing how to listen.